RSCI (Redwood Scientific Technologies) Loans Receivable: $0.00 Mil (As of Dec. 2023)


What is Redwood Scientific Technologies Loans Receivable?

Redwood Scientific Technologies RSCI Loans Receivable is $0.00 Mil as of Dec. 2023.

Redwood Scientific Technologies's Loans Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Redwood Scientific Technologies Loans Receivable Related Terms

Redwood Scientific Technologies Loans Receivable Historical Data

* Premium members only.

The historical data trend for Redwood Scientific Technologies's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Redwood Scientific Technologies Loans Receivable Chart

Redwood Scientific Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Loans Receivable
0.00 0.00 0.00 0.00

Redwood Scientific Technologies Semi-Annual Data
Dec20 Dec21 Dec22 Dec23
Loans Receivable 0.00 0.00 0.00 0.00

Redwood Scientific Technologies Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Redwood Scientific Technologies (RSCI) has a Loans Receivable of $0.00 Mil as of Dec. 2023. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Redwood Scientific Technologies and its competitors.
Is Redwood Scientific Technologies' Loans Receivable too high?
Redwood Scientific Technologies' current Loans Receivable is $0.00 Mil.
How does Redwood Scientific Technologies' Loans Receivable compare to RAPH and FLGC?
Redwood Scientific Technologies' Loans Receivable of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Drug Manufacturers company?
A good Loans Receivable depends on the Drug Manufacturers industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Redwood Scientific Technologies and its competitors. Redwood Scientific Technologies's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redwood Scientific Technologies stock overvalued right now?
Redwood Scientific Technologies (RSCI) has a current Loans Receivable of $0.00 Mil. The current Loans Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Redwood Scientific Technologies (RSCI), the current Loans Receivable is $0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Redwood Scientific Technologies Business Description

Address 418 Broadway, STE 4872, Albany, NY, USA, 12207
Redwood Scientific Technologies Inc is a pharmaceutical delivery company that develops, operates, and markets over-the-counter products in a sublingual oral thin film strip. RSCI has begun clinical trials on two new products to market for stopping the addiction to nicotine.